Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-s-landmark-approvals-of-bms-schizo-med-madrigal-s-mash-drug-us-16-5-bn-catalent-buyout-make-it-to-top-10-news-of-2024
19 Dec 2024
// ACCESSWIRE
https://www.accesswire.com/957501/mira-pharmaceuticals-submits-ind-for-ketamir-2-to-fda-marking-a-significant-milestone-in-the-companys-pipeline-development
10 Dec 2024
// ACCESSWIRE
https://www.accesswire.com/952344/mira-pharmaceuticals-validates-ketamir-2s-safety-profile-with-no-adverse-findings-paving-the-way-for-ind-submission-by-year-end
20 Nov 2024
// ACCESSWIRE
https://www.accesswire.com/944828/mira-reveals-innovative-phase-iiia-protocol-design-and-selection-of-clinical-trial-site
28 Oct 2024
// ACCESSWIRE
https://www.accesswire.com/935612/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved-gabapentin-in-reversing-chemotherapy-induced-neuropathic-pain
21 Oct 2024
// ACCESSWIRE
https://www.accesswire.com/932046/mira-pharmaceuticals-announces-ketamir-2-outperforms-current-fda-approved-neuropathic-pain-treatments-gabapentin-and-pregabalin-in-preclinical-study
18 Sep 2024
// ACCESSWIRE
https://www.accesswire.com/919382/mira-pharmaceuticals-advances-ketamir-2-development-following-phase-1-design-completion-focusing-on-early-clinical-efficacy-demonstration-for-neuropathic-pain-in-2025
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?